Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.83 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.83 |
| ▸ | HPGD | P15428 | 6/20 | 0.83 |
| ▸ | HSD17B10 | Q99714 | 6/20 | 0.83 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.83 |
| ▸ | RAB9A | P51151 | 7/20 | 0.71 |
| ▸ | MAPT | P10636 | 6/20 | 0.71 |
| ▸ | NPC1 | O15118 | 5/20 | 0.71 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.71 |
| ▸ | MEN1 | O00255 | 4/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.71 |
| ▸ | TP53 | P04637 | 2/20 | 0.71 |
| ▸ | XDH | P47989 | 1/20 | 0.64 |
| ▸ | USP2 | O75604 | 1/20 | 0.60 |
| ▸ | GLA | P06280 | 1/20 | 0.60 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.58 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.58 |
| ▸ | RELA | Q04206 | 1/20 | 0.58 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.58 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17718217 | 0.92 | KDM4E (0.76) | KDM4EALDH1A1HPGDHSD17B10CYP3A4 | |
| 2'-Methoxyformonetin SCHEMBL234355 | 0.91 | KDM4E (1.00) | KDM4EALDH1A1HPGDHSD17B10CYP3A4 | |
| 2'-Methoxyformonetin SCHEMBL29777010 | 0.91 | KDM4E (1.00) | KDM4EALDH1A1HPGDHSD17B10CYP3A4 | |
| SCHEMBL4832045 | 0.90 | RAB9A (0.72) | KDM4EALDH1A1HPGDHSD17B10CYP3A4 | |
| SCHEMBL5241998 | 0.89 | MAPT (0.74) | KDM4EALDH1A1HPGDHSD17B10CYP3A4 | |
| SCHEMBL2971118 | 0.86 | XDH (0.76) | KDM4EALDH1A1HPGDHSD17B10CYP3A4 | |
| SCHEMBL27916248 | 0.85 | KDM4E (0.80) | KDM4EALDH1A1HPGDHSD17B10CYP3A4 | |
| SCHEMBL7056427 | 0.84 | CYP3A4 (0.76) | KDM4EALDH1A1HPGDHSD17B10CYP3A4 | |
| SCHEMBL1675988 | 0.83 | RAB9A (0.71) | KDM4EALDH1A1HPGDHSD17B10CYP3A4 | |
| SCHEMBL762092 | 0.83 | MAPT (1.00) | KDM4EALDH1A1HPGDHSD17B10CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2016073947-A1 | ANTI-VIRAL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | Kineta, Inc. (US) | 2016-05-12 | — | — | WO | disclosed |
| US-20160122312-A1 | ANTI-VIRAL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE THEREOF | Kineta, Inc. | 2016-05-05 | — | — | US | disclosed |
| WO-2015009812-A2 | ANTI-VIRAL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | Kineta, Inc. (US) | 2015-01-22 | — | — | WO | disclosed |
| US-6589980-B2 | A compound which is 2,6-dihydroxy-8-methoxy-10,11-dioxa-benzo(b)fluoren-5-one or a pharmaceutically acceptable salt for treating or inhibiting osteoporosis or inhibiting bone demineralization in a mammal in need thereof | WYETH | 2003-07-08 | — | — | US | disclosed |
| US-20030087955-A1 | Substituted 10,11-benzo[b]fluoren-10-ones as estrogenic agents | WYETH | 2003-05-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030087955-A1 | Substituted 10,11-benzo[b]fluoren-10-ones as estrogenic agents | ESR1, GPER1, ESR2 | KDM4E 437/4885ALDH1A1 1276/4885HPGD 3155/4885 |
| US-20160122312-A1 | ANTI-VIRAL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE THEREOF | MAVS, EIF2AK2, IRF3 | KDM4E 2241/4885ALDH1A1 3052/4885HPGD 3295/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.